β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis

F. Bagnato, R. Zivadinov, D. Cecchinelli, A. Tancredi, A. Grop, A. Pierallini, C. De Lena, M. Prencipe, G. Reale, M. Zorzon, E. Millefiorini

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Beta2-microglobulin (β2-MG) is a pharmacodynamic marker of interferon-β activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of β2-MG in free-treatment MS patients during a short-time course to quantify β2-MG as a marker of disease activity/ progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of β2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of β2-MG were similar in patients and HI. Patients' β2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of β2-MG as a surrogate marker of disease in MS.

Original languageEnglish
Pages (from-to)455-460
Number of pages6
JournalEuropean Journal of Neurology
Volume11
Issue number7
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Multiple Sclerosis
Serum
Interferons
Disease Progression
Biomarkers
Enzyme-Linked Immunosorbent Assay
Steroids
Recurrence
Brain
Therapeutics

Keywords

  • Beta2-microglobulin
  • Biological marker
  • Disease activity
  • Gadolinium-enhancing lesions
  • Inflammation
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. / Bagnato, F.; Zivadinov, R.; Cecchinelli, D.; Tancredi, A.; Grop, A.; Pierallini, A.; De Lena, C.; Prencipe, M.; Reale, G.; Zorzon, M.; Millefiorini, E.

In: European Journal of Neurology, Vol. 11, No. 7, 07.2004, p. 455-460.

Research output: Contribution to journalArticle

Bagnato, F, Zivadinov, R, Cecchinelli, D, Tancredi, A, Grop, A, Pierallini, A, De Lena, C, Prencipe, M, Reale, G, Zorzon, M & Millefiorini, E 2004, 'β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis', European Journal of Neurology, vol. 11, no. 7, pp. 455-460. https://doi.org/10.1111/j.1468-1331.2004.00808.x
Bagnato, F. ; Zivadinov, R. ; Cecchinelli, D. ; Tancredi, A. ; Grop, A. ; Pierallini, A. ; De Lena, C. ; Prencipe, M. ; Reale, G. ; Zorzon, M. ; Millefiorini, E. / β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. In: European Journal of Neurology. 2004 ; Vol. 11, No. 7. pp. 455-460.
@article{4cdb7a7c1c5d4dd2a44b4dd6c9516a79,
title = "β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis",
abstract = "Beta2-microglobulin (β2-MG) is a pharmacodynamic marker of interferon-β activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of β2-MG in free-treatment MS patients during a short-time course to quantify β2-MG as a marker of disease activity/ progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of β2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7{\%}) patients experienced a clinical relapse but three (10{\%}) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of β2-MG were similar in patients and HI. Patients' β2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of β2-MG as a surrogate marker of disease in MS.",
keywords = "Beta2-microglobulin, Biological marker, Disease activity, Gadolinium-enhancing lesions, Inflammation, Multiple sclerosis",
author = "F. Bagnato and R. Zivadinov and D. Cecchinelli and A. Tancredi and A. Grop and A. Pierallini and {De Lena}, C. and M. Prencipe and G. Reale and M. Zorzon and E. Millefiorini",
year = "2004",
month = "7",
doi = "10.1111/j.1468-1331.2004.00808.x",
language = "English",
volume = "11",
pages = "455--460",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - β2-microglobulin serum level is not a marker of disease activity in multiple sclerosis

AU - Bagnato, F.

AU - Zivadinov, R.

AU - Cecchinelli, D.

AU - Tancredi, A.

AU - Grop, A.

AU - Pierallini, A.

AU - De Lena, C.

AU - Prencipe, M.

AU - Reale, G.

AU - Zorzon, M.

AU - Millefiorini, E.

PY - 2004/7

Y1 - 2004/7

N2 - Beta2-microglobulin (β2-MG) is a pharmacodynamic marker of interferon-β activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of β2-MG in free-treatment MS patients during a short-time course to quantify β2-MG as a marker of disease activity/ progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of β2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of β2-MG were similar in patients and HI. Patients' β2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of β2-MG as a surrogate marker of disease in MS.

AB - Beta2-microglobulin (β2-MG) is a pharmacodynamic marker of interferon-β activity in multiple sclerosis (MS). Its role in the natural course of the disease is not fully known. We analyzed the spontaneous fluctuation of β2-MG in free-treatment MS patients during a short-time course to quantify β2-MG as a marker of disease activity/ progression. Thirty MS patients were clinically assessed and imaged monthly over a 3-month period. Sera were collected concomitantly for the evaluation of β2-MG, by means of an enzyme-linked immunosorbent assay. Sera from 20 healthy individuals (HI) were drawn and used as controls. The Mann-Whitney test was used when appropriate and time effect on radiological and biological measures was assessed by means of the random effect models. Eight (26.7%) patients experienced a clinical relapse but three (10%) required steroid treatment. A reduction in the contrast-enhancing lesion load (P = 0.02) and a trend (P = 0.07) toward a decrease in brain parenchyma fraction were observed. Baseline levels of β2-MG were similar in patients and HI. Patients' β2-MG values increased over the 3-month time period (P = 0.05) but did not exceed those detected in HI at any time point. These results failed to demonstrate the validity of β2-MG as a surrogate marker of disease in MS.

KW - Beta2-microglobulin

KW - Biological marker

KW - Disease activity

KW - Gadolinium-enhancing lesions

KW - Inflammation

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=3843089602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843089602&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2004.00808.x

DO - 10.1111/j.1468-1331.2004.00808.x

M3 - Article

C2 - 15257683

AN - SCOPUS:3843089602

VL - 11

SP - 455

EP - 460

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 7

ER -